Certolizumab pegol Completed Phase 3 Trials for Crohn's Disease (CD)

IndicationsStatusPurposePhase
CompletedNot Available3
clinicaltrials.gov IdentifierTitleDrugs
NCT00152490A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)
NCT00152425Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).